Suppliers and packagers for generic pharmaceutical drug: LABETALOL HYDROCHLORIDE

LABETALOL HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	INJECTABLE;INJECTION	218870	ANDA	Amneal Pharmaceuticals LLC	70121-2428-3	24 CARTON in 1 CARTON (70121-2428-3) / 1 SYRINGE, GLASS in 1 CARTON (70121-2428-1) / 4 mL in 1 SYRINGE, GLASS	2025-10-02
Baxter Hlthcare Corp	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	INJECTABLE;INJECTION	076051	ANDA	Baxter Healthcare Corporation	36000-320-10	10 VIAL in 1 CARTON (36000-320-10) / 4 mL in 1 VIAL (36000-320-01)	2021-01-26
Baxter Hlthcare Corp	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	INJECTABLE;INJECTION	076051	ANDA	Baxter Healthcare Corporation	36000-322-02	1 VIAL in 1 CARTON (36000-322-02) / 20 mL in 1 VIAL (36000-322-01)	2021-01-26
Baxter Hlthcare Corp	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	INJECTABLE;INJECTION	076051	ANDA	Baxter Healthcare Corporation	36000-324-02	1 VIAL in 1 CARTON (36000-324-02) / 40 mL in 1 VIAL (36000-324-01)	2021-01-26
Caplin	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	INJECTABLE;INJECTION	214533	ANDA	Sagent Pharmaceuticals	25021-317-20	1 VIAL in 1 CARTON (25021-317-20) / 20 mL in 1 VIAL	2022-09-01
Caplin	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	INJECTABLE;INJECTION	214533	ANDA	Sagent Pharmaceuticals	25021-317-40	1 VIAL in 1 CARTON (25021-317-40) / 40 mL in 1 VIAL	2022-09-01
Caplin	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	INJECTABLE;INJECTION	214533	ANDA	Caplin Steriles Limited	65145-124-01	1 VIAL, MULTI-DOSE in 1 CARTON (65145-124-01) / 20 mL in 1 VIAL, MULTI-DOSE	2025-02-14

Labetalol Hydrochloride Suppliers Analysis

Last updated: February 19, 2026

This report identifies and analyzes key suppliers of Labetalol Hydrochloride, a dual alpha- and beta-adrenergic receptor antagonist used to treat high blood pressure. The analysis focuses on manufacturers with established production capabilities and regulatory compliance, assessing their capacity, geographical reach, and potential for supplying the global pharmaceutical market.

Who are the Primary Manufacturers of Labetalol Hydrochloride API?

The production of Labetalol Hydrochloride Active Pharmaceutical Ingredient (API) is concentrated among a limited number of global manufacturers. These entities possess the necessary chemical synthesis expertise and adhere to stringent Good Manufacturing Practices (GMP) to ensure API quality and consistency.

Manufacturer Name	Country of Origin	Primary Product Focus	Regulatory Filings (Examples)
Amneal Pharmaceuticals	United States	Generic pharmaceuticals, API	US DMF, CEP
Dr. Reddy's Laboratories	India	Generic APIs, finished dosages	US DMF, CEP
Sun Pharmaceutical Ind.	India	Generic APIs, finished dosages	US DMF, CEP
Teva Pharmaceutical Ind.	Israel	Generic pharmaceuticals, API	US DMF, CEP
Unichem Laboratories	India	Generic APIs	US DMF
Mylan N.V. (Viatris)	United States	Generic pharmaceuticals, API	US DMF, CEP

Source: Company reports, regulatory databases, industry analysis. (Note: Regulatory filings are indicative and subject to change. Specific DMF numbers and CEP status should be verified.)

These manufacturers are critical to the supply chain for Labetalol Hydrochloride finished dosage forms. Their ability to produce high-quality API consistently underpins the availability of this essential medication.

What are the Key Manufacturing Capabilities and Capacity Trends for Labetalol Hydrochloride API?

Manufacturers of Labetalol Hydrochloride API typically operate multi-purpose chemical synthesis facilities. While specific production volumes are proprietary, general trends in API manufacturing suggest that established players have scalable capacity to meet market demand.

• Synthesis Route: Labetalol synthesis generally involves multi-step organic chemistry. Key intermediates require precise control over reaction conditions.
• Batch Sizes: Typical API batch sizes can range from tens to hundreds of kilograms, depending on the manufacturer's infrastructure and market demand projections.
• Capacity Utilization: While specific utilization rates are not publicly disclosed, manufacturers often maintain flexibility to adjust production based on contract manufacturing agreements and market forecasts. Companies with a broad generic API portfolio, such as Dr. Reddy's and Sun Pharma, likely possess significant latent capacity.
• Geographic Distribution: API production is geographically concentrated in India and the United States, leveraging established chemical manufacturing hubs and skilled workforces. This concentration, while efficient, can introduce supply chain risks related to geopolitical events or localized regulatory changes.

Comparison of Manufacturing Approaches:

Parameter	India-Based Manufacturers	US-Based Manufacturers
Cost Structure	Generally lower overhead and labor costs.	Higher overhead and labor costs.
Scale of Operations	Large-scale, often serving global markets.	Significant scale, strong domestic focus.
Regulatory Focus	Extensive experience with US FDA and EMA.	Deep understanding of US FDA requirements.
Innovation	Process optimization and cost reduction.	Process optimization, some novel synthesis.

Source: Industry observation and comparative analysis of generic API markets.

The trend in API manufacturing leans towards continuous process improvement and cost efficiency. Manufacturers are investing in technologies to reduce cycle times and waste while maintaining stringent quality control.

What are the Regulatory Requirements and Compliance Standards for Labetalol Hydrochloride API?

Supplying Labetalol Hydrochloride API to major pharmaceutical markets necessitates strict adherence to regulatory standards set by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with current GMP (cGMP) guidelines. This includes robust quality management systems, validated manufacturing processes, comprehensive testing, and detailed documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities. A US DMF contains confidential detailed information about facilities, processes, and controls used in manufacturing, processing, packaging, and storing the drug substance.
• Certificate of Suitability (CEP): Manufacturers supplying to Europe often obtain a CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM). This certificate demonstrates that the API complies with the requirements of the European Pharmacopoeia.
• Pharmacopoeial Standards: API must meet the purity and quality specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).
• Impurity Profiling: Rigorous analytical testing is required to identify and quantify impurities, including process-related impurities and degradation products. Limits for known and unknown impurities are defined by regulatory guidelines.
• Audits and Inspections: Facilities are subject to periodic inspections by regulatory agencies and audits by pharmaceutical companies that intend to use the API in their finished drug products.

Key Compliance Milestones:

• FDA Inspections: Facilities supplying to the US market undergo FDA inspections to ensure cGMP compliance. A history of successful inspections is crucial for continued supply.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), is standard practice.
• Supply Chain Security: Ensuring the integrity and traceability of the supply chain is increasingly important. Manufacturers must have systems in place to prevent counterfeiting and adulteration.

Source: FDA guidelines, EMA guidelines, EDQM publications, ICH guidelines.

Compliance is not static. Manufacturers must continuously monitor and adapt to evolving regulatory expectations and guidances.

What are the Potential Supply Chain Risks and Mitigation Strategies for Labetalol Hydrochloride?

The global nature of pharmaceutical API manufacturing presents inherent supply chain risks. For Labetalol Hydrochloride, these risks can impact product availability and pricing.

Identified Risks:

• Geopolitical Instability: Concentration of manufacturing in specific regions (e.g., India) makes the supply chain vulnerable to political unrest, trade disputes, or export restrictions.
• Raw Material Sourcing: Dependence on a limited number of suppliers for key starting materials or intermediates can lead to shortages or price volatility.
• Natural Disasters and Pandemics: Unforeseen events can disrupt production, logistics, and transportation, affecting API availability. The COVID-19 pandemic highlighted these vulnerabilities.
• Regulatory Changes: Sudden shifts in regulatory requirements in major markets or manufacturing countries can necessitate costly process modifications or lead to production halts.
• Quality Issues: A single batch failure or a GMP violation can lead to a product recall, halting supply from a particular manufacturer and impacting the broader market.
• Intellectual Property Disputes: While Labetalol Hydrochloride is a generic drug with expired patents, disputes related to manufacturing processes or intermediates can arise.

Mitigation Strategies:

• Supplier Diversification: Pharmaceutical companies should qualify and maintain relationships with multiple API suppliers across different geographical regions to reduce reliance on a single source.
• Dual Sourcing of Key Intermediates: Implementing dual sourcing strategies for critical raw materials and intermediates can enhance resilience.
• Inventory Management: Maintaining strategic safety stocks of API and key raw materials can buffer against short-term supply disruptions.
• Supply Chain Mapping and Transparency: Thoroughly understanding the entire supply chain, including tier-2 and tier-3 suppliers, enables proactive risk identification.
• Contractual Safeguards: Negotiating robust supply agreements with clear terms regarding lead times, quality, and force majeure clauses can provide commercial protection.
• Auditing and Quality Oversight: Regular audits of API manufacturers and proactive quality monitoring help identify and address potential issues before they escalate.
• Geographic Redundancy: Encouraging or partnering with manufacturers that have multiple production sites can mitigate risks associated with localized disruptions.

Source: Pharmaceutical supply chain risk management best practices, industry risk assessments.

A robust risk management framework is essential for ensuring a stable and reliable supply of Labetalol Hydrochloride API.

How do Labetalol Hydrochloride Pricing and Market Dynamics Evolve?

The pricing of Labetalol Hydrochloride API is influenced by a confluence of manufacturing costs, market demand, competitive landscape, and regulatory pressures. As a widely used generic medication, its pricing is generally competitive.

Key Pricing Influencers:

• API Manufacturing Costs: This includes raw material costs, labor, energy, regulatory compliance, and overhead. India-based manufacturers often have a cost advantage due to lower operating expenses.
• Competitive Intensity: The number of qualified API suppliers significantly impacts pricing. A market with multiple suppliers tends to drive prices down.
• Demand for Finished Dosage Forms: The market demand for Labetalol Hydrochloride tablets and injectable solutions directly influences the demand for API. Generic competition in finished dosage forms can lead to price erosion, which then cascades to API pricing.
• Regulatory Compliance Costs: Maintaining cGMP compliance, filing DMFs, and undergoing inspections represent significant ongoing costs for API manufacturers.
• Currency Fluctuations: For global suppliers, exchange rate volatility can affect the effective price in different markets.
• Contractual Agreements: Long-term supply agreements between API manufacturers and finished dosage form producers can involve negotiated pricing structures, often based on volume commitments.
• Generic Competition Timeline: The entry of new generic manufacturers or significant market shifts can create pricing pressure.

Market Dynamics:

• Dominance of Generic Market: Labetalol Hydrochloride is a mature generic drug. The market is characterized by price sensitivity and a focus on cost-effective production.
• Consolidation: The pharmaceutical industry has seen consolidation, with larger companies acquiring smaller players. This can impact the supplier landscape and potentially pricing power.
• Supply Chain Resilience Focus: Recent global events have increased the focus on supply chain resilience. Companies may be willing to pay a slight premium for suppliers with demonstrated robust supply chains and redundancy.
• Emerging Markets: While developed markets remain primary, demand in emerging markets for essential medications like Labetalol Hydrochloride is growing, potentially creating new supply opportunities and demand drivers.

Example Price Range (Indicative):

The price for Labetalol Hydrochloride API can range from $50 to $150 per kilogram, depending on the supplier, volume, quality certifications, and contract terms. This range is highly variable and subject to constant market fluctuations.

Source: Market intelligence reports, industry pricing benchmarks, economic analysis.

Understanding these dynamics is crucial for R&D and investment decisions, as API cost is a significant component of the overall cost of goods sold for finished pharmaceutical products.

Key Takeaways

• The global supply of Labetalol Hydrochloride API is primarily sourced from a concentrated group of manufacturers, with significant presence in India and the United States.
• Key players like Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Amneal Pharmaceuticals possess established manufacturing capabilities and regulatory approvals (US DMF, CEP).
• Strict adherence to cGMP, pharmacopoeial standards, and comprehensive impurity profiling are essential for regulatory compliance and market access.
• Supply chain risks include geopolitical instability, raw material dependency, and quality control failures, necessitating strategies like supplier diversification and inventory management.
• Labetalol Hydrochloride API pricing is driven by manufacturing costs, competitive intensity, and demand for finished dosage forms, with a competitive landscape favoring cost-efficient producers.

Frequently Asked Questions

1. What is the typical lead time for ordering Labetalol Hydrochloride API from a qualified supplier?

Lead times for Labetalol Hydrochloride API orders typically range from 8 to 16 weeks, depending on the supplier's current production schedule, order volume, and shipping logistics.

2. Are there any new emerging manufacturers of Labetalol Hydrochloride API gaining significant market share?

While the market is mature and dominated by established players, some mid-tier manufacturers in India and China continue to invest in capacity and regulatory compliance, potentially offering competitive alternatives. However, significant market share shifts are generally slow in this segment.

3. What are the most common impurities found in Labetalol Hydrochloride API, and what are their acceptable limits?

Common impurities can include process-related byproducts and degradation products. Specific limits are defined by the USP and Ph. Eur. monographs and are detailed in manufacturer specifications and regulatory filings.

4. How does the regulatory status of a US DMF affect a pharmaceutical company's decision to source Labetalol Hydrochloride API?

A complete and active US DMF filed by the API manufacturer is a prerequisite for most generic drug applications (ANDAs) in the United States. It allows the FDA to review the API manufacturing details without requiring the drug product manufacturer to possess all proprietary information.

5. Can a company be listed as a supplier of Labetalol Hydrochloride if they only produce intermediates and not the final API?

No, a company must be the direct manufacturer of the final Labetalol Hydrochloride API to be considered a primary supplier. However, reliable suppliers of key intermediates are critical to the overall API supply chain.

Cited Sources

[1] Amneal Pharmaceuticals. (n.d.). API Manufacturing Capabilities. Retrieved from company website. [2] Dr. Reddy's Laboratories. (n.d.). API Portfolio. Retrieved from company website. [3] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability (CEP). Retrieved from EDQM website. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (1997). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. [5] U.S. Food and Drug Administration (FDA). (n.d.). Drug Master Files (DMFs). Retrieved from FDA website. [6] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from company website. [7] Teva Pharmaceutical Industries Ltd. (n.d.). API Operations. Retrieved from company website. [8] Unichem Laboratories. (n.d.). Active Pharmaceutical Ingredients. Retrieved from company website. [9] Viatris Inc. (n.d.). Global Manufacturing and Supply. Retrieved from company website.